This article is written by Helena Strigård and Jonathan Royce.
Having returned from a series of conferences staged in the spring of 2023, when barely any event missed the opportunity to highlight ATMPs through presentations and panel discussions, we felt that there is a general desire to grasp what this toolbox really means for those of us operating in life sciences.
Consequently, we put together this overview of what’s cooking in the space. The text that follows is based specifically on the talks and panel sessions held at the BIO International Convention 2023, with a ‘sneak peek’ forward to the upcoming Nordic Life Science Days, where ATMPs will again be at the top of the agenda.
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
The complex journey of bringing a biologic to market – part 6 As SOL-116 progresses toward Phase II trials, stability becomes a central focus in ensuring the product remains safe, ...
When we hosted the workshop “Growing Together: Navigating CDMO Partnerships Through Clinical Phases” at Nordic Life Science Days in Gothenburg, we hoped to start a dialogue about what truly makes ...
The complex journey of bringing a biologic to market – part 5 With GMP production of SOL-116 completed, the focus shifts to Fill & Finish—the step where drug substance becomes ...